Reports Q2 revenue $730K, consensus $1.13M. “In the second quarter of 2025, data from our now completed Phase 2 study in chronic spontaneous urticaria were presented that we believe clearly show that barzolvolimab is best in disease and achieves the goal of treatment for patients and physicians-rapid, profound, durable complete response which is correlated with meaningful improvements in quality of life,” said Anthony Marucci, co-founder, president and CEO of Celldex (CLDX) Therapeutics. “The Celldex team is working diligently to bring this important medicine to patients and we remain focused on executing across our Phase 3 program in CSU, which is on track and expected to be fully enrolled next summer.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLDX:
- CLDX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Celldex Therapeutics’ Phase 3 Study on Barzolvolimab: A Potential Game-Changer for Chronic Urticaria
- Celldex Therapeutics’ Phase 3 Study: A Potential Breakthrough for Chronic Urticaria
- Celldex Therapeutics’ Promising Phase 2 Study on Barzolvolimab for Prurigo Nodularis
- RBC downgrades Jasper Therapeutics on questions about briquilimab